Comparative clinical study· 2008

Efficacy and possible mechanisms of action of a new peptide anxiolytic Selank in the therapy of generalized anxiety disorders and neurasthenia

Zozulia AA|et al.

Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova

PubMed
18454096
Evidence level
low
Verification
verified

Summary

Comparative study of Selank and medazepam in 62 patients.

Limitations

Small study|Comparator rather than placebo|Regional publication|Limited blinding information

Linked peptides

Important PeptiBrief is an educational information platform. It does not diagnose, prescribe, sell peptides, recommend dosing, encourage self-experimentation or replace qualified medical care. Published scientific evidence is kept separate from community observations and uncertainty.